Inter J Stomatol ›› 2018, Vol. 45 ›› Issue (2): 125-131.doi: 10.7518/gjkq.2018.02.001
• Expert Forum • Next Articles
Wang Zhi
CLC Number:
| [1] 李敏, 宋文婷, 林梅. 炎症性肠病的口腔损害及其诊断[J]. 国际口腔医学杂志, 2010, 37(3):330-332. Li M, Song WT, Lin M.Oral lesion of inflammatory bowel disease and its diagnosis[J]. Int J Stomatol, 2010, 37(3):330-332. [2] Baumgart DC, Carding SR.Inflammatory bowel disease: cause and immunobiology[J]. Lancet, 2007, 369(9573):1627-1640. [3] Atarashi K, Suda W, Luo C, et al.Ectopic coloni-zation of oral bacteria in the intestine drives T(H)1 cell induction and inflammation[J]. Science, 2017, 358(6361):359-365. [4] Katsanos KH, Torres J, Roda G, et al.Review article: non-malignant oral manifestations in inflammatory bowel diseases[J]. Aliment Pharmacol Ther, 2015, 42(1):40-60. [5] Álvarez-Garrido H, Pericet-Fernández L, Martínez-García G, et al.Crohn’s disease and cheilitis granu-lomatosa: role of silicone fillers[J]. J Am Acad Der-matol, 2011, 65(1):239-241. [6] Stawarski A, Iwańczak B, Krzesiek E, et al.Intestinal complications and extraintestinal manifestations in children with inflammatory bowel disease[J]. Pol Merkur Lekarski, 2006, 20(115):22-25. [7] Tan CX, Brand HS, de Boer NK, et al. Gastrointes-tinal diseases and their oro-dental manifestations: part 2: ulcerative colitis[J]. Br Dent J, 2017, 222(1):53-57. [8] Lankarani KB, Sivandzadeh GR, Hassanpour S.Oral manifestation in inflammatory bowel disease: a review[J]. World J Gastroenterol, 2013, 19(46):8571-8579. [9] Ciacci C, Bucci C, Zingone F, et al.Buccal localiza-tion of Crohn’s disease with long-term infliximab the-rapy: a case report[J]. J Med Case Rep, 2014, 8:397. [10] Ben Salah R, Frikha F, Snoussi M, et al.Limited form of Wegener’s granulomatosis in a patient with Crohn’s disease. A case report[J]. Turk J Gastroenterol, 2014, 25(Suppl 1):191-195. [11] Bohra S, Kariya PB, Bargale SD, et al.Clinicopatho-logical significance of Melkersson-Rosenthal syn-drome[J]. BMJ Case Rep, 2015, 2015:bcr2015210138. [12] Sciubba JJ, Said-Al-Naief N. Orofacial granuloma-tosis: presentation, pathology and management of 13 cases[J]. J Oral Pathol Med, 2003, 32(10):576-585. [13] Rivera-Serrano CM, Man LX, Klein S, et al.Melker-sson-Rosenthal syndrome: a facial nerve center perspective[J]. J Plast Reconstr Aesthet Surg, 2014, 67(8):1050-1054. [14] Liu R, Yu S.Melkersson-Rosenthal syndrome: a review of seven patients[J]. J Clin Neurosci, 2013, 20(7):993-995. [15] Dai C, Li J, Yang S, et al.Subtotal facial nerve decom-pression for recurrent facial palsy in Melkersson Ro-senthal syndrome[J]. Acta Otolaryngol, 2014, 134(4): 425-428. [16] Ziem PE, Pfrommer C, Goerdt S, et al.Melkersson-Rosenthal syndrome in childhood: a challenge in differential diagnosis and treatment[J]. Br J Der-matol, 2000, 143(4):860-863. [17] Okudo J, Oluyide Y.Melkersson-Rosenthal syndrome with orofacial swelling and recurrent lower motor neuron facial nerve palsy: a case report and review of the literature[J]. Case Rep Otolaryngol, 2015, 2015:214946. [18] Liu R, Yu S.Melkersson-Rosenthal syndrome: a review of seven patients[J]. J Clin Neurosci, 2013, 20(7):993-995. [19] Ziemssen F, Rohrbach JM, Scherwitz C, et al.Plastic reconstructive correction of persistent orofacial swe-lling and swelling of the eyelids in Melkersson-Rosenthal syndrome[J]. Klin Monbl Augenheilkd, 2003, 220(5):352-356. [20] Kanerva M, Moilanen K, Virolainen S, et al.Melker-sson-Rosenthal syndrome[J]. Otolaryngol Head Neck Surg, 2008, 138(2):246-251. [21] Chen ES, Moller DR.Etiologies of sarcoidosis[J]. Clin Rev Allergy Immunol, 2015, 49(1):6-18. [22] Moller DR, Chen ES.What causes sarcoidosis[J]. Curr Opin Pulm Med, 2002, 8(5):429-434. [23] Motswaledi MH, Khammissa RA, Jadwat Y, et al.Oral sarcoidosis: a case report and review of the literature[J]. Aust Dent J, 2014, 59(3):389-394. [24] Zoon JJ.Chronic benign circumscript plasmocytic balanoposthitis[J]. Dermatologica, 1952, 105(1):1-7. [25] Yang JH, Lee UH, Jang SJ, et al.Plasma cell cheilitis treated with intralesional injection of corticosteroids[J]. J Dermatol, 2005, 32(12):987-990. [26] Tamaki K, Osada A, Tsukamoto K, et al.Treatment of plasma cell cheilitis with griseofulvin[J]. J Am Acad Dermatol, 1994, 30(5 Pt 1):789-790. [27] Hanami Y, Motoki Y, Yamamoto T.Successful treat-ment of plasma cell cheilitis with topical tacrolimus: report of two cases[J]. Dermatol Online J, 2011, 17(2):6. [28] Yamaguchi Y, Nishie W, Ito T, et al.Plasma cell cheilitis successfully treated with topical calcineurin inhibitors[J]. Eur J Dermatol, 2016, 26(6):609-610. [29] Yoshimura K, Nakano S, Tsuruta D, et al.Successful treatment with 308-nm monochromatic excimer light and subsequent tacrolimus 0.03% ointment in re-fractory plasma cell cheilitis[J]. J Dermatol, 2013, 40(6):471-474. [30] Madhavarajan S, Tighe J.Orofacial plasmacytosis: a management conundrum[J]. Br J Oral Maxillofac Surg, 2015, 53(4):399-402. [31] Laffer WB.Blepharochalasis. Report of a case of this trophoneurosis, involving also the upper lip[J]. Cleveland Med J, 1909, 8:131-135. [32] Ascher KW.Blepharochalasis mit struma und dop-pellippe[J]. Klin Monatsbl Augenheilkd, 1920, 65: 86-89. [33] 郭丽丽, 刘林嶓. Ascher综合征的整形外科治疗[J]. 中国美容医学, 2009, 18(3):287-289. Guo LL, Liu LB.Plastic surgical treatment in 16 cases of Ascher’s syndrome[J]. Chin J Aesth Med, 2009, 18(3):287-289. [34] 董雪, 唐晓军. Ascher综合征[J]. 中国美容医学, 2012, 21(10):1886-1887. Dong X, Tang XJ.Ascher syndrome[J]. Chin J Aesth Med, 2012, 21(10):1886-1887. [35] Molina S, Medard P, Galdeano M.Ascher syndrome: report of a case with early manifestations[J]. Cranio-maxillofac Trauma Reconstr, 2015, 8(2):150-152. [36] Beggs AD, Latchford AR, Vasen HF, et al.Peutz-Jeghers syndrome: a systematic review and recom-mendations for management[J]. Gut, 2010, 59(7): 975-986. [37] 袁文娟, 曹丽珍. 口周色素沉着-肠息肉综合征[J]. 上海口腔医学, 2001, 10(4):319-320. Yuan WJ, Cao LZ.Peutz-Jeghers syndrone: report of 4 cases[J]. Shanghai J Stomatol, 2001, 10(4):319-320. [38] 张同贞, 温洪涛. 口周色素沉着-肠道息肉综合征的发病机制[J]. 肿瘤基础与临床, 2010, 23(6):541-543. Zhang TZ, Wen HT.The pathogenesis of Peutz-Jeghers syndrome[J]. J Basic Clin Oncol, 2010, 23(6):541-543. [39] Ge Y, Jia G, Lin T.Q-switched Nd:YAG laser treat-ment for labial lentigines associated with Peutz-Jeghers syndrome[J]. J Dtsch Dermatol Ges, 2015, 13(6):551-555. [40] Løvås K, Husebye ES.Addison’s disease[J]. Lancet, 2005, 365(9476):2058-2061. [41] Quinkler M.Addison’s disease[J]. Med Klin Inten-sivmed Notfmed, 2012, 107(6):454-459. [42] Napier C, Pearce SH.Current and emerging thera-pies for Addison’s disease[J]. Curr Opin Endocrinol Diabetes Obes, 2014, 21(3):147-153. [43] Michels A, Michels N.Addison disease: early detec-tion and treatment principles[J]. Am Fam Physician, 2014, 89(7):563-568. [44] Laugier P, Hunziker N.Essential lenticular melanic pigmentation of the lip and cheek mucosa[J]. Arch Belg Dermatol Syphiligr, 1970, 26(3):391-399. [45] Nikitakis NG, Koumaki D.Laugier-Hunziker syn-drome: case report and review of the literature[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 116(1):e52-e58. [46] Kemmett D, Ellis J, Spencer MJ, et al.The Laugier-Hunziker syndrome—a clinical review of six cases[J]. Clin Exp Dermatol, 1990, 15(2):111-114. [47] Wei Z, Li GY, Ruan HH, et al.Laugier-Hunziker syndrome: a case report[J]. J Stomatol Oral Maxillo-fac Surg, 2017. [Epub ahead of print] [48] Ko JH, Shih YC, Chiu CS, et al.Dermoscopic features in Laugier-Hunziker syndrome[J]. J Dermatol, 2011, 38(1):87-90. [49] Sinha S, Schwartz RA.Juvenile acanthosis nigri-cans[J]. J Am Acad Dermatol, 2007, 57(3):502-508. [50] Kutlubay Z, Engin B, Bairamov O, et al.Acanthosis nigricans: a fold (intertriginous) dermatosis[J]. Clin Dermatol, 2015, 33(4):466-470. [51] 姚辉, 周曾同. 口腔黏膜黑棘皮病(附二例报告)[J]. 临床口腔医学杂志, 2010, 26(5):297-299. Yao H, Zhou ZT.Acanthosis acanthosis in oral mucosa (report of two cases)[J]. J Clin Stomatol, 2010, 26(5):297-299. [52] Canjuga I, Mravak-Stipetić M, Kopić V, et al.Oral acanthosis nigricans: case report and comparison with literature reports[J]. Acta Dermatovenerol Croat, 2008, 16(2):91-95. [53] Hermanns-Lê T, Scheen A, Piérard GE.Acanthosis nigricans associated with insulin resistance: patho-physiology and management[J]. Am J Clin Dermatol, 2004, 5(3):199-203. [54] Ezzedine K, Eleftheriadou V, Whitton M, et al.Vitiligo[J]. Lancet, 2015, 386(9988):74-84. [55] Nagarajan A, Masthan MK, Sankar LS, et al.Oral manifestations of vitiligo[J]. Indian J Dermatol, 2015, 60(1):103. [56] Rodrigues M, Ezzedine K, Hamzavi I, et al.Current and emerging treatments for vitiligo[J]. J Am Acad Dermatol, 2017, 77(1):17-29. [57] 黄海艳, 王芳, 柯宜均, 等. 特殊部位白癜风的治疗进展[J]. 中国皮肤性病学杂志, 2013, 27(1):81-84. Huang HY, Wang F, Ke YJ, et al.Advances in the treatment of vitiligo on special sites[J]. Chin J Derm Venereol, 2013, 27(1):81-84. [58] Wang D, Goh BK.Noncultured epidermal cell suspension, in combination with carbon dioxide laser, improves punch grafting complications[J]. Dermatol Surg, 2017, 43(8):1100-1103. |
| [1] | Li Xin,Li Yan,Ding Xu,Xia Boyuan,Yu Weixian. Role of endoplasmic reticulum stress in periodontitis affecting systemic diseases [J]. Int J Stomatol, 2021, 48(1): 12-17. |
| [2] | Kaixian Yan,Shu Li. Non-periodontal gingival lesions [J]. Inter J Stomatol, 2019, 46(2): 177-185. |
| [3] | Liu Jinli, Chen Fangman, Jiang Lu.. Drug management of oral submucous fibrosis [J]. Inter J Stomatol, 2017, 44(3): 325-331. |
| [4] | Li Yan, He Jinzhi, Xiao Liying, Zhou Xuedong.. Oral microbiome and diseases [J]. Inter J Stomatol, 2014, 41(1): 118-122. |
| [5] | YIN Xiao-peng, LIN Zhao -quan.. The perioperative risk evaluation and regulation of elder patients with oral and maxillofacial tumor [J]. Inter J Stomatol, 2010, 37(5): 573-575. |